HematologySanofi
Sanofi Reports Positive ATLAS Trial Results for Fitusiran in Hemophilia A and B
BMI
Biotechnology Media Insights
Editorial Team · May 22, 2025
Sanofi announces positive Phase 3 ATLAS trial results showing fitusiran significantly reduces bleeding rates in hemophilia A and B patients with and without inhibitors.
Sanofi today announced positive results from the Phase 3 ATLAS clinical program evaluating fitusiran in patients with hemophilia A or B with and without inhibitors. The trials demonstrated significant reductions in annualized bleeding rates compared to on-demand factor replacement therapy.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.